CHKB Antibody

What are the key considerations when selecting a CHKB antibody for research applications?

When selecting a CHKB antibody for research applications, researchers should consider:

• Antibody specificity: Determine whether the antibody detects endogenous levels of total CHKB protein or specific regions (e.g., C-terminal, internal regions, or specific amino acid sequences) .

• Host species and clonality: Most commercially available CHKB antibodies are rabbit polyclonal antibodies, though mouse polyclonal options exist .

• Application compatibility: Verify validation for your intended application (WB, IHC, IF, ELISA, ICC) .

• Epitope region: Different antibodies target different regions of CHKB, such as AA 2-99, AA 1-395, or C-terminal regions .

• Conjugation: Available in unconjugated forms or conjugated to markers like HRP, FITC, or Biotin depending on experimental needs .

• Validation data: Review scientific validation images and published research utilizing the antibody to confirm its reliability in your experimental context .

How should CHKB antibodies be stored and handled to maintain optimal activity?

For optimal CHKB antibody performance:

• Store at -20°C as recommended by manufacturers .

• Maintain in appropriate buffer systems (typically phosphate buffered saline without Mg²⁺ and Ca²⁺, pH 7.4, 150mM NaCl, with preservatives like 0.02% sodium azide and 50% glycerol) .

• Avoid repeated freeze-thaw cycles, which can degrade antibody performance.

• For diluted working solutions, prepare fresh and use within 24 hours when possible.

• When using conjugated antibodies (HRP, FITC, Biotin), protect from light exposure during storage and handling.

• Optimal working dilution should be determined experimentally for each specific application and sample type .

What are the optimal protocols for using CHKB antibodies in immunoblotting experiments?

Western Blotting Protocol for CHKB Detection:

• Sample Preparation:

  • Extract proteins from cell lines (validated in HepG2 and A549 cells) or tissue samples

  • Include protease inhibitors to prevent degradation

  • Quantify protein concentration for equal loading

• Gel Electrophoresis:

  • Load 20-50 μg of protein per lane

  • Separate proteins using 10-12% SDS-PAGE (CHKB is approximately 45 kDa)

• Transfer and Blocking:

  • Transfer to PVDF or nitrocellulose membrane

  • Block with 5% non-fat dry milk or BSA in TBST for 1 hour at room temperature

• Primary Antibody Incubation:

  • Dilute CHKB antibody (typically 1:500-1:2000) in blocking buffer

  • Incubate overnight at 4°C with gentle rocking

• Secondary Antibody:

  • Use appropriate anti-rabbit or anti-mouse HRP-conjugated secondary antibody

  • Goat Anti-Rabbit IgG H&L Antibody (HRP) is suitable for rabbit primary antibodies

  • Dilute 1:5000-1:10000 in blocking buffer

  • Incubate for 1 hour at room temperature

• Detection:

  • Develop using ECL substrate

  • Expected band size: 45 kDa for full-length CHKB

This protocol has been validated using extracts from HepG2 and A549 cell lines .

How can researchers implement CHKB antibodies in chromatin immunoprecipitation (ChIP) assays?

While the search results don't specifically mention ChIP protocols for CHKB antibodies, researchers can adapt standard ChIP protocols based on similar nuclear protein studies:

• Chromatin Preparation:

  • Cross-link cells with 1% formaldehyde for 10 minutes at room temperature

  • Lyse cells in appropriate buffer (150 mM NaCl, 25 mM Tris pH 7.5, 1% Triton X-100, 0.1% SDS, 0.5% deoxycholate with protease inhibitors and PMSF)

  • Fragment DNA to ~200 bp using sonication

• Immunoprecipitation:

  • Use 200 μg of protein lysate per IP reaction

  • Incubate with 2-5 μg of CHKB antibody overnight at 4°C

  • Include IgG control from the same species as the CHKB antibody

  • Add protein A/G beads and incubate for 2-4 hours

• Washing and Elution:

  • Wash beads with increasing stringency buffers

  • Elute protein-DNA complexes and reverse cross-links

• DNA Purification and Analysis:

  • Purify DNA using phenol-chloroform extraction or commercial kits

  • Analyze by qPCR using primers specific to regions of interest

  • Confirm enrichment compared to IgG control and input samples

This approach is based on similar ChIP protocols that have been successful for nuclear proteins .

What are the key functions of CHKB in normal cellular physiology?

CHKB (choline kinase beta) plays several critical physiological roles:

• Phospholipid Biosynthesis:

  • Catalyzes the first step in the biosynthetic pathway for phosphatidylcholine, a major membrane phospholipid

  • Forms functional homo- or hetero-dimeric complexes with CHKA

• Mitochondrial Function Regulation:

  • Influences mitochondrial respiratory enzyme activities

  • Affects mitochondrial membrane composition

  • Modulates oxygen consumption rate (OCR) and energy metabolism

• Fatty Acid Metabolism:

  • Involved in fatty acid β-oxidation pathways

  • Influences triacylglycerol levels when disrupted

• Tissue-Specific Functions:

  • Shows differential expression patterns compared to CHKA

  • Particularly important in muscle and cardiac tissue development and function

• Developmental Roles:

  • Unlike CHKA (whose knockout is embryonically lethal), CHKB is not essential for embryonic development but is crucial for postnatal growth and development

Understanding these functions provides context for investigating CHKB in disease states and developing targeted research strategies.

How is CHKB implicated in cardiomyopathy and muscular dystrophy pathogenesis?

CHKB dysfunction contributes to several disease mechanisms:

Cardiomyopathy:

• CHKB-deficient mice exhibit cardiac hypertrophy with decreased left ventricle size, internal diameter, and stroke volume

• 60% of heterozygous and all homozygous CHKB-knockout mice display arrhythmic events when challenged with isoproterenol

• Lipidomic analysis shows alterations in cardiac tissue lipid profiles

• CHKB deficiency impairs mitochondrial function in cardiac tissue, with significantly lower oxygen consumption rates in all respiratory states when using palmitoyl-carnitine as substrate

• A long noncoding RNA called CHKB-DT is significantly downregulated in dilated cardiomyopathy, and its knockdown impairs mitochondrial function and decreases ATP production

Muscular Dystrophy:

• Homozygous loss-of-function variants in human CHKB are associated with congenital muscular dystrophy

• CHKB deficiency leads to megaconial congenital muscular dystrophy (MCMD), characterized by enlarged mitochondria and impaired mitochondrial function

• Inactivation of CHKB in mice results in a rostral-to-caudal muscular dystrophy pattern

• By 2-3 months of age, CHKB-deficient mice lose hindlimb motor control

• Serum creatine kinase (CK) activity is 2-3 fold higher in CHKB-deficient mice compared to wild type

Case Studies:
A 13-year-old male with a homozygous nonsense variant (c.598delC, p.Q200Rfs*11) of the CHKB gene presented with mild intellectual disability and severe cardiac impairment, including reduced activity tolerance, suspected acute heart failure, significant cardiac enlargement, and heart blocks .

What are the current challenges in using CHKB antibodies for investigating mitochondrial dysfunction in disease models?

Several technical challenges exist when using CHKB antibodies to study mitochondrial dysfunction:

• Subcellular Localization Complexity:

  • CHKB's dynamic localization between cytosolic and mitochondrial compartments requires careful sample preparation and fractionation protocols

  • Antibodies may show different affinities for CHKB depending on its post-translational modifications or binding partners in different cellular compartments

• Tissue-Specific Expression Variations:

  • Expression levels and isoform distribution vary across tissues, necessitating validation in each specific tissue type

  • Antibody sensitivity must be sufficient to detect endogenous levels in tissues with lower expression

• Model-Specific Considerations:

  • When using mouse models (CHKB−/− mice), researchers must account for species-specific epitope differences

  • Differences in disease progression between human patients and animal models may affect the timing of CHKB expression changes

• Distinguishing CHKA from CHKB:

  • High sequence homology between CHKA and CHKB requires careful antibody selection to ensure specificity

  • Cross-reactivity testing is essential, particularly in tissues where both isoforms are expressed

• Functional Assessment Integration:

  • Correlating antibody-based detection with functional assays (like the Seahorse XF24 extracellular flux analyzer measurements) requires careful experimental design

  • Antibody-based findings should be validated using multiple methodologies

How can researchers integrate CHKB antibody staining with mitochondrial functional assays?

To effectively combine CHKB antibody detection with mitochondrial functional analysis:

• Sequential Analysis Protocol:

  • Perform mitochondrial functional assays (e.g., Seahorse XF analysis) on live cells

  • Fix cells immediately after functional measurements

  • Proceed with immunostaining using validated CHKB antibodies

  • This approach allows direct correlation between CHKB expression and mitochondrial function in the same cell population

• Co-localization Studies:

  • Use CHKB antibodies in conjunction with established mitochondrial markers (e.g., TOMM20, MitoTracker dyes)

  • Implement confocal microscopy to assess co-localization coefficients

  • Quantify the degree of association between CHKB and functional mitochondrial parameters

• Integrated Analysis Workflow:
  a. Isolate mitochondria and assess oxygen consumption rates using substrates like palmitoyl-carnitine
  b. Measure sequential respiratory states using oligomycin, FCCP, and antimycin A/rotenone
  c. Process parallel samples for CHKB immunoblotting
  d. Correlate CHKB protein levels with functional parameters

• Combined In Vivo Approaches:

  • For mouse models, perform cardiac functional assessments (echocardiography)

  • Collect tissue for both mitochondrial functional assays and CHKB immunohistochemistry

  • Compare CHKB expression patterns with regional differences in mitochondrial function

• Data Integration Framework:

  • Develop quantitative methods to correlate CHKB expression levels with specific mitochondrial functional parameters

  • Consider machine learning approaches to identify patterns between CHKB localization/expression and functional outcomes

What are the best approaches for validating CHKB antibody specificity in experimental systems?

To ensure CHKB antibody specificity, researchers should implement a comprehensive validation strategy:

• Genetic Validation:

  • Use CHKB knockout or knockdown models (siRNA/shRNA) as negative controls

  • Overexpression systems as positive controls

  • Compare antibody signal between wild-type, heterozygous, and homozygous knockout samples

• Multi-antibody Approach:

  • Validate findings using multiple antibodies targeting different epitopes (e.g., AA 2-99, C-terminal regions)

  • Compare results between polyclonal and monoclonal antibodies when available

• Cross-reactivity Assessment:

  • Test for potential cross-reactivity with CHKA due to sequence homology

  • Include recombinant CHKA and CHKB proteins as controls

• Application-specific Validation:

  • For Western blotting: Confirm single band at expected molecular weight (approximately 45 kDa)

  • For immunohistochemistry/immunofluorescence: Include peptide competition assays

  • For immunoprecipitation: Verify pull-down using mass spectrometry

• Tissue Expression Correlation:

  • Compare antibody staining patterns with known tissue expression profiles

  • Correlate with mRNA expression data from independent techniques

• Reproducibility Testing:

  • Test antibody performance across different lots

  • Validate across different cell lines with known CHKB expression (e.g., HepG2, A549)

Implementing these validation steps ensures confidence in experimental findings and facilitates meaningful interpretation of CHKB-related biological processes.

How can CHKB antibodies be used to investigate the relationship between phospholipid metabolism and mitochondrial function?

CHKB antibodies can serve as valuable tools for exploring the phospholipid-mitochondria connection through:

• Co-immunoprecipitation Studies:

  • Use CHKB antibodies to pull down associated proteins involved in mitochondrial function

  • Identify novel interaction partners that may connect phospholipid metabolism to mitochondrial processes

  • Combine with mass spectrometry for unbiased identification of the CHKB interactome

• Lipid Microdomains Investigation:

  • Employ CHKB antibodies alongside specialized membrane fractionation techniques

  • Determine CHKB localization relative to mitochondria-associated membranes (MAMs)

  • Correlate CHKB localization with specific phospholipid compositions

• Temporal Dynamics Analysis:

  • Track CHKB localization changes during mitochondrial stress responses

  • Monitor phosphatidylcholine synthesis in relation to mitochondrial functional states

  • Research has shown temporal changes in lipid metabolism in CHKB-deficient muscle, with initial inability to utilize fatty acids for energy via mitochondrial β-oxidation

• Therapeutic Testing Platforms:

  • Screen compounds that modulate CHKB function or localization

  • Assess mitochondrial functional outcomes using assays like Seahorse XF analysis

  • Evaluate potential rescue of mitochondrial defects in disease models

• Multi-omics Integration:

  • Combine CHKB immunoprecipitation with lipidomics and proteomics

  • Create comprehensive maps of CHKB-associated lipid and protein networks

  • This approach has revealed that the major change in lipid level in CHKB-deficient cardiac tissue involves specific phospholipid species

What computational approaches are being developed to optimize antibody-based research tools for CHKB investigation?

While not specific to CHKB antibodies, emerging computational approaches relevant to antibody optimization include:

• Zero-shot Computational Design:

  • Generative unconstrained intelligent drug engineering (GUIDE) platforms combine high-performance computing, simulation, and machine learning to optimize binding affinity

  • Similar approaches could be applied to enhance CHKB antibody specificity and sensitivity

• Multi-target Optimization:

  • Computational methods can co-optimize binding to multiple targets simultaneously

  • For CHKB research, this could enable development of antibodies that recognize conserved epitopes across species or distinguish between CHKA and CHKB with higher specificity

• Simulation-Based Affinity Prediction:

  • Molecular dynamics and free energy perturbation techniques predict binding characteristics

  • These methods could guide the selection of optimal CHKB epitopes for antibody generation

• Machine Learning for Epitope Selection:

  • AI approaches identify optimal antibody binding regions

  • Particularly valuable for designing antibodies against specific CHKB domains associated with particular functions

• Structural Biology Integration:

  • Leveraging protein structure information (like the CHKB protein structure AF-Q9Y259-F1) to guide antibody design

  • Analysis of how mutations (such as p.Q200Rfs*11) affect protein structure can inform the development of mutation-specific antibodies